Genenta Science SpA ADR
Yahoo Finance • 6 days ago
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in oncology, today announc... Full story
Yahoo Finance • 11 days ago
Earnings Momentum Lifts PACS And Nutex; Zynex And Genenta Also Advance After Hours
(RTTNews) - Several stocks posted notable moves in Wednesday's after-hours session, extending momentum from the regular trading day or reversing earlier trends. Earnings announcements and recent financing updates shaped activity across hea... Full story
Yahoo Finance • last month
Biggest stock movers Monday: RNA, HIVE, and more
[Active trader analyzes market trends using smartphone in a dark setting] FabrikaCr/iStock via Getty Images Stock futures edged higher in Monday's premarket session as optimism over a potential US-China trade deal and a widely expected Fe... Full story
Yahoo Finance • last month
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors to purchase 4,285,7... Full story
Yahoo Finance • last month
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration w... Full story
Yahoo Finance • 5 months ago
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme (TEM-GBM) study, wit... Full story
Yahoo Finance • 8 months ago
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global Biotech Tour” in Doha... Full story
Yahoo Finance • 8 months ago
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million($21.9 million) financing through the issuance of a... Full story
Yahoo Finance • 2 years ago
Genenta to Present at Upcoming Scientific and Investor Conferences
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a perm... Full story
Yahoo Finance • 2 years ago
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable an... Full story
Yahoo Finance • 3 years ago
Genenta to Provide Update on Lead Product Temferon™
MILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini, Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage immuno-oncology company, will be presen... Full story
Yahoo Finance • 3 years ago
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net exchange rate gain of €2.3 millionTax credit of €6.4 million MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Ge... Full story
Yahoo Finance • 3 years ago
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications
MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable a... Full story
Yahoo Finance • 3 years ago
Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement
MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a dev... Full story
Yahoo Finance • 3 years ago
Genenta Provides First Half 2022 Business Update and Financial Results
Current dose escalation study data shows a median overall survival of 17 months Adding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30, 2022, providing a c... Full story
Yahoo Finance • 3 years ago
AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative
MILAN, Italy, July 25, 2022 (GLOBE NEWSWIRE) -- Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and expansion in their interactions with U.S. financia... Full story
Yahoo Finance • 4 years ago
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be p... Full story
Yahoo Finance • 4 years ago
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development
MILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces... Full story
Yahoo Finance • 4 years ago
Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme
No dose limiting toxicity observed in previous three dose level cohorts Represents a 50% higher dose than highest prior level Update of guidance for trial MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NA... Full story
Yahoo Finance • 4 years ago
Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma
MILAN, Italy and NEW YORK, May 02, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces... Full story
